FDA Panel to Review MDMA Therapy for PTSD

In a landmark session, the FDA will assess MDMA's potential as the first psychedelic therapy for PTSD in the U.S.

On June 4, FDA advisers will decide on recommending MDMA, known as ecstasy, for PTSD treatment.
This marks the first review of a new PTSD therapy by an FDA panel in 25 years.
Lykos Therapeutics has conducted extensive studies on MDMA's efficacy in conjunction with psychotherapy.
No psychedelic-based treatments have yet been approved for mental health disorders in the U.S.
The therapy combines MDMA with psychological interventions to enhance patient outcomes.